Mannell A, Winters Z
Department of Surgery, Baragwanath Hospital, Johannesburg.
S Afr Med J. 1989 Sep 2;76(5):213-4.
Cisplatin has modest activity in squamous cancer of the oesophagus but substantial toxicity limits its usefulness. Carboplatin (Paraplatin; BM Group), a second-generation platinum analogue, was developed to maintain the antitumour activity of cisplatin and reduce toxicity. Eleven patients with advanced oesophageal cancer were treated with carboplatin. A partial response was seen in 1 patient (9%) and minor responses in 2 cases. The median survival was 12 months in responding patients and 3 months in non-responders. One patient suffered reversible myelosuppression but nephrotoxicity and vomiting were not observed. Carboplatin is well tolerated and may have a role as a less toxic substitute for cisplatin in combination chemotherapy regimens for oesophageal cancer.
顺铂对食管鳞状癌有一定活性，但严重的毒性限制了其应用。第二代铂类类似物卡铂（Paraplatin；BM集团）旨在维持顺铂的抗肿瘤活性并降低毒性。11例晚期食管癌患者接受了卡铂治疗。1例患者出现部分缓解（9%），2例出现轻微缓解。缓解患者的中位生存期为12个月，未缓解患者为3个月。1例患者出现可逆性骨髓抑制，但未观察到肾毒性和呕吐。卡铂耐受性良好，在食管癌联合化疗方案中，作为毒性较低的顺铂替代物可能有一定作用。
